Keryx Biopharmaceuticals, Inc. (KERX) Downgraded by ValuEngine
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.
Several other research firms have also issued reports on KERX. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, June 17th. Maxim Group set a $9.00 target price on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Wednesday, July 12th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $7.00 target price (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.48.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 0.43% on Thursday, hitting $6.95. The company had a trading volume of 864,963 shares. The firm has a 50 day moving average of $7.01 and a 200-day moving average of $6.55. Keryx Biopharmaceuticals has a 12-month low of $4.11 and a 12-month high of $8.38. The firm’s market capitalization is $825.31 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.51 million. During the same quarter in the previous year, the company posted ($0.42) EPS. The business’s revenue was up 62.4% on a year-over-year basis. On average, equities analysts predict that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/23/keryx-biopharmaceuticals-inc-kerx-downgraded-by-valuengine.html.
A number of large investors have recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. raised its stake in Keryx Biopharmaceuticals by 51.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,628 shares during the period. The Manufacturers Life Insurance Company raised its stake in Keryx Biopharmaceuticals by 4.0% in the second quarter. The Manufacturers Life Insurance Company now owns 66,161 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 2,564 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Keryx Biopharmaceuticals in the second quarter valued at approximately $183,000. Gotham Asset Management LLC bought a new stake in Keryx Biopharmaceuticals in the second quarter valued at approximately $402,000. Finally, Stifel Financial Corp raised its stake in Keryx Biopharmaceuticals by 8.0% in the second quarter. Stifel Financial Corp now owns 36,447 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 2,711 shares during the period. Hedge funds and other institutional investors own 65.19% of the company’s stock.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.